Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 29;9(6):638. doi: 10.1038/s41419-018-0701-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a RT-qPCR analysis of gene expression of Runx2, alkaline phosphatase (ALP), bone sialoprotein (BSP), osteocalcin (OCN) in BMSCs cultured in the osteogenic medium and treated with different concentrations of dexamethasone for 14 days. b RT-qPCR analysis of gene expression of adipogenic differentiation markers, including peroxisome proliferator-activated receptor gamma (PPARγ) and fatty acid-binding protein 4 (FABP4) in BMSCs. c RT-qPCR analysis of gene expression of renin–angiotensin system (RAS), including angiotensin-converting enzyme (ACE), angiotensin receptors (ATRs), and ELISA analysis of angiotensin II (Ang II) production in BMSCs cultured in the osteogenic medium and treated with different concentrations of dexamethasone for 14 days. d Western blotting assay of ACE, AT1R, and AT2R protein level in BMSCs. e Alizarin Red S staining for mineralization nodules after co-treating BMSCs with dexamethasone and ACE inhibitor (ACEI) during the process of osteogenic differentiation. f RT-qPCR analysis of gene expression of Runx2, ALP, BSP, and OCN after co-treating BMSCs with dexamethasone and ACEI. g RT-qPCR analysis of gene expression of PPARγ and FABP4 after co-treating BMSCs with dexamethasone and ACEI. All experiments were performed at least three times. Mean ± S.E.M., ^*P < 0.05, ^**P < 0.01 compared with the untreated cells